NR1H4 and metabolic dysfunction-associated steatotic liver disease: In a mouse model of NAFLD, McMahan et al. reported that treatment of genetically obese db/db mice with dual bile acid FXR/TGR5 receptor agonist INT-767 reduced hepatic expression of profibrotic/proinflammatory genes and ameliorated the histological features of NAFLD.